Research4 days ago 4 min read
KPV reduces inflammatory markers in early IBD trial
A 60-patient pilot study tested oral KPV in patients with mild ulcerative colitis.
by Editorial team
Design
Sixty patients with mild-to-moderate ulcerative colitis were randomized to oral KPV or placebo for 8 weeks alongside standard care.
Endoscopic and biochemical markers were measured at baseline and week 8.
Findings
The KPV group showed reductions in fecal calprotectin and CRP versus placebo.
Endoscopic improvement was modest and not statistically significant.
Next steps
Larger trials with longer duration are planned.
The peptide is not currently approved for any IBD indication.